Perrigo Outlines 2025 Growth Plans, Projects Sales Boost And Margin Expansion By 2027
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 28 2025
0mins
Source: Benzinga
Financial Projections: Perrigo Company plc's shares rose significantly after announcing financial targets for 2025, including expected sales growth of 1% to 3%, adjusted EPS of $2.90 – $3.10, and a strategy focused on stabilizing, streamlining, and strengthening its operations.
Recent Performance: The company reported fourth-quarter adjusted EPS of $0.93, slightly below estimates, with sales of $1.14 billion also falling short of expectations; however, the stock price increased by 21.3% following the announcements.
Analyst Views on PRGO
Wall Street analysts forecast PRGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRGO is 20.33 USD with a low forecast of 18.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 14.910
Low
18.00
Averages
20.33
High
23.00
Current: 14.910
Low
18.00
Averages
20.33
High
23.00
About PRGO
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
